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short- and longer-term effectiveness of EECP. Although the ENBS depends on the 
cost-effectiveness threshold, the ENBS is positive for most sample sizes indicating that 
further experimental research will be efﬁ cient. A clinical trial design is proposed with 
equal allocation of patients between arms. Given a threshold of a20,000 per QALY 
gained, the highest expected returns to additional research will come from a trial with
a 4-year follow-up and an optimal sample size of 900. CONCLUSIONS: Expert elici-
tation and value of sample information can be combined into a single coherent 
framework to establish the value of further research, the optimal design of such
research, and the most appropriate basis for informing cost-effectiveness.
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OBJECTIVES: To compare one-day cost efﬁ cacy and safety of enoxaparin 1 mg/kg
subcutaneous injection twice daily with unfractionated heparin intravenous infusion 
for the conservative management in patients with NSTE-ACS. METHODS: Eighty
patients were enrolled in the study and received enoxaparin 10 mg/kg subcutaneous 
injection twice daily (n  40) or unfractionated heparin intravenous infusion (n  40) 
for the conservative management in patients with NSTE-ACS. Treatment efﬁ cacy was
evaluated on the basis of the combination of clinical, ECG and laboratory indexes. 
The therapy was considered to be non-effective in case of death, nonfatal myocardial 
infarction (MI), early angiography with subsequent revascularization and major bleed-
ing. RESULTS: Total expenses per 1 patient (only direct costs) and cost/efﬁ cacy ratio
were calculated for each anticoagulant group. The following cases were recorded in 
unfractionated heparin group: one death, two major bleedings, and ﬁ ve MIs. Treat-
ment efﬁ cacy proved to be 80% while total expenses per 1 patient stood at 46,489
rubles and cost/efﬁ cacy ratio accounted for 58,111 rubles per every effective treatment
(current exchange rate 1$  29 rubles). Enoxaparin showed 3 MIs and 1 performed
acute angioplasty. Treatment efﬁ cacy was 90% while total expenses per 1 patient was 
46,993 rubles and cost/efﬁ cacy ratio was 52 214 rubles per 1 effective treatment. After
compare the costs of treatment and its efﬁ cacy in both groups enoxaparin proved to 
be the most cost-effective anticoagulant due to the smallest total expenses and cost/
efﬁ cacy ratio. CONCLUSIONS: Medical treatment with enoxaparin 1 mg/kg twice
daily in patients with NSTE-ACS proved to be more beneﬁ cial in terms of cost and 
efﬁ cacy than permanent intravenous infusion of unfractionated heparin.
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OBJECTIVES: Updated consensus guidelines published by the American College of 
Chest Physicians, and the International Union of Angiology recommend thrombopro-
phylaxis with either low-molecular-weight heparin or unfractionated heparin(UFH) in
medical patients at risk of VTE. The purpose of this study was to estimate the cost-
effectiveness of different thromboprophylactic agents to prevent or treat VTE associ-
ated with patients undergoing general surgery from the institutional perspective. 
METHODS: A six-state Markov model was performed to estimate health and eco-
nomic consequences during a time horizon of one year (1-week cycles). Effectiveness
measures were decreased number of deep vein thrombosis(DVT) and pulmonary 
thromboembolism(PE) events; reduction of recurrent hospitalizations and avoidance
of death. Transition probabilities were obtained from a meta-analysis employing inter-
national published literature. Comparators used in the assessment were warfarin(5 mg/
day); dalteparin(2,500,5,000,7,500 IU/day); acenocoumarol(4 mg/day); enoxaparin 
(20,40,60 mg/day); nadroparin(57,00 IU/day); UFH plus warfarin(10,000,30,000,42,
000 IU/day5 mg/day) and fondaparinux(2.5–7.5 mg/day). Resource use and costs 
were obtained from 8000 randomized hospital records from the Social Security 
Mexican Institute (IMSS) and ofﬁ cial institutional databases. Costs include outpatient
and inpatient services, drug, procedures, etc. The model was validated according to 
international guidelines. Probabilistic sensitivity analyses were performed employing 
bootstrapping techniques. Acceptability curves were constructed. RESULTS: Daltepa-
rin showed the lowest incidence of PE, DVT, thrombosis associated deaths and hospital
recurrence compared to the rest of thromboprophylactic therapies(p  0.05). Only
warfarin and acenocoumarol obtained costs below dalteparin strategy. Regarding the 
reduction of DVT events, dalteparin 2500, 5000 and 7000 IU/day show an ICER
[CI95%] of US$110.0[US$107.7–US$112.3]; US$101.3[US$99.1–US$103.5] and 
US$97.3[US$93.8–US$97.9] against warfarin (gold-standard), respectively. Enoxapa-
rin 20,40,60 mg/day; nadroparin and UHFwarfarin were dominated by dalteparin. 
Second-order Monte Carlo analysis showed that dalteparin could be a cost-saving 
treatment against enoxaparin with a probability over 50%. Component analyses 
further validated these results. CONCLUSIONS: Dalteparin is a cost-effective throm-
boprophylactic therapy to reduce PE and DVT events in Mexican medical patients at 
risk of VTE due its higher efﬁ cacy and lower cost.
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OBJECTIVES: A high risk to develop pulmonary thromboembolism (PE) and deep 
vein thrombosis (DVT) has been associated with certain surgeries and prolonged hos-
pitalization. The aim of this study was to assess the cost-effectiveness of different
anticoagulant therapies to prevent or treat VTE associated with hip surgery from 
the health care payer’s perspective. METHODS: A six-state stochastic Markov model 
was performed to estimate costs and effectiveness during a time horizon of one-year 
(1-week cycles). Effectiveness measures were reduction in PE and DVT events; 
decreased hospitalizations and avoidance of death. Transition probabilities were 
obtained from a meta-analysis involving national and international published litera-
ture. Comparators used in the assessment were warfarin(5 mg/day); dalteparin
(2500,5000,7500 IU/day); acenocoumarol(4 mg/day); enoxaparin(20,40,60 mg/day); 
nadroparin(5700 IU/day); unfractionated heparin plus warfarin(10000,30000,42000 
IU/day5 mg/day) and fondaparinux(2.5–7.5 mg/day). Resource use and costs were 
obtained from hospital records (n  8000) from the Social Security Mexican Institute
(IMSS) and ofﬁ cial institutional databases. Costs include outpatient and inpatient 
services, drug, procedures, etc. The model was validated according to international 
guidelines. Sensitivity analyses were performed employing bootstrapping techniques 
and acceptability curves were constructed. RESULTS: Incidence of PE and DVT were 
signiﬁ cantly lower in patients receiving dalteparin treatment (p  0.05). Regarding
the reduction of DVT events, dalteparin 2500, 5000 and 7000 IU/day showed
an ICER[CI95%] of US$214.02[US$209.47–US$218.58]; US$198.65[US$194.43–
US$202.89] and US$189.06[US$185.04–US$193.09] against warfarin, respectively.
Dalteparin showed the lowest number of deaths and hospital re-admissions when
compared to other anticoagulant treatments(p  0.05) reducing signiﬁ cant costs in the 
short term within an institutional Mexican setting. Second-order Monte Carlo analy-
ses showed evidence that dalteparin would be more cost-effective than enoxaparin in 
a range of 60%–70%(p  0.05). CONCLUSIONS: In Mexico, dalteparin demon-
strated to be a cost-effective anticoagulant therapy to reduce the incidence of PE and
DVT, and avoid death and hospital re-admissions in the management of adult patients
after total hip replacement. These results should be taken into account by Mexican 
health professionals to generate cost-containment strategies.
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OBJECTIVES: Patients treated with total knee arthroplasty are at high risk for the 
development of venous thromboembolism postoperatively resulting in poor health
outcomes and generating additional costs to the health care system. The purpose of 
this study was to estimate the cost-effectiveness of different thromboprophylactic
agents to prevent VTE associated with knee surgery from an institutional perspective.
METHODS: A six-state stochastic Markov model was constructed to simulate health
and economic outcomes during a time horizon of one year (1-week cycles). Effective-
ness measures were prevention of events of deep vein thrombosis (DVT) and pulmonary 
thromboembolism(PE); and reduction of recurrent hospitalizations and deaths.
Markov transition probabilities were obtained from a meta-analysis employing 
international published literature. Comparators employed were warfarin(5 mg/day); 
dalteparin(2,500,5,000,7,500 IU/day); enoxaparin (20,40,60 mg/day); nadroparin
(57,00 IU/day); unfractionated heparin(UFH) plus warfarin(10,000,30,000,42,000 IU/
day5 mg/day); fondaparinux(2.5–7.5 mg/day) and no prophylaxis intervention.
Resource use and costs were collected from clinical records (n  7000) from Social
Security Mexican Institute(IMSS) hospitals. Costs include outpatient and inpatient 
services, drug, procedures, etc. The model was calibrated according to international 
guidelines. Probabilistic sensitivity analyses were performed employing bootstrapping
techniques and acceptability curves were constructed. RESULTS: Incidence of PE 
and related deaths were signiﬁ cantly lower for patients treated with dalteparin
(p  0.05). Regarding the prevention of PE events, dalteparin 2500, 5000 and 7000 IU/
day showed an ICER[CI95%] of US$1932.88[US$1,888.67–US$1977.11];
US$1800.87[US$1759.67–US$1842.07] and US$1718.52[US$1679.21–US$1757.84]; 
against warfarin(gold-standard), respectively. In addition, UFH yielded an ICER of 
US$23.35[US$22.82–US$23.89] and fondaparinux of US$1410.74[US$1378.47–
US$1,443.02]. However, enoxaparin, nadroparin, and no prophylaxis alternatives 
were dominated. Second-order Monte Carlo sensitivity analyses demonstrated a trend
that dalteparin would be more cost-effective than enoxaparin in a range of 50%–
60%(p  0.05) in PE events avoided. CONCLUSIONS: At IMSS, dalteparin compared 
to warfarin would be a cost-effective thromboprophylactic therapy to reduce risk
of PE and DVT events associated with total knee arthroplasty and showed 75% 
less related deaths than enoxaparin. These results could be useful for future cost-
containment policies.
